Head-to-head · free
SURG vs Tessera Technologies
SURG vs TSRA — return on capital, cash generation, margins and balance sheet side by side.
SURG
0 / 0
measures where SURG leads
TSRA
0 / 0
measures where TSRA leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | SURG · FY2025 | TSRA |
|---|---|---|
| Revenue | $57.0M | — |
| Net income | (36.1M) | — |
| Revenue growth (yearly, multi-year) | 2.8% | — |
| Free cash flow | (21.3M) | — |
| Free cash flow margin | -37.4% | — |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | — | — |
| Gross margin | -18.6% | — |
| Operating margin | -53.8% | — |
| Net debt / EBITDA | -0.35x | — |
Figures are as reported by each company; latest fiscal year shown.
Where SURG's cash went (FY2025)
- Capital spending
- $18590
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free